QL9-21

QL9-21 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, Mar 18, 2026: “LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on QL9-21

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • 2 of 2 findings with company ties
  • Animals1

What did studies of QL9-21 find?

2

Studies of QL9-21 measured 2 outcomes: liver accumulation and viral genome delivery to brain.

Liver accumulation

downin non-human primates1

1 study
  1. QL9-21 decreases liver accumulation in non-human primates (2.6 fold reduction).

    “while concurrently reducing liver accumulation by 2.6 fold”

    Animalsliver

    LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates

    bioRxivPreprint

Viral genome delivery to brain

upin non-human primates1

1 study
  1. QL9-21 increases viral genome delivery to brain in non-human primates (3-40 fold enhancement).

    “mediated a striking 3-40 fold enhancement in viral genome delivery across all examined brain regions versus AAV9”

    Animalsbrain

    LRP6-Guided Engineering of AAV9 Variants with Enhanced Blood-Brain Barrier Penetration and Reduced Liver Tropism in Non-Human Primates

    bioRxivPreprint

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months